Skip to main navigation
Ventyx Biosciences, Inc. Ventyx Biosciences, Inc.
  • About
    • Overview
    • Leadership
    • Board of Directors
    • Advisory Board
    • Contact
  • Science
  • Pipeline
    • Overview
    • VTX958
    • VTX002
    • VTX2735
    • VTX3232
  • Investors
    • Overview
    • News & events
    • Stock information
    • Governance
    • Financials & filings
    • IR resources
  • Careers
  • News Releases
  • Events
  • Presentations

News Releases

News Releases

December 6, 2021
Ventyx Biosciences Announces First Patient Dosed in a Phase 2 Clinical Trial of VTX002 for the Treatment of Moderate-to-Severe Ulcerative Colitis
Read more
November 19, 2021
Ventyx Biosciences to Participate in Two Upcoming Investor Conferences
Read more
November 17, 2021
Ventyx Biosciences Reports Third Quarter Financial Results and Provides Business Update
Read more
October 25, 2021
Ventyx Biosciences Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Read more
October 20, 2021
Ventyx Biosciences Announces Pricing of Upsized Initial Public Offering
Read more
September 20, 2021
Ventyx Biosciences Announces Key Appointments and Closing of $51.0 Million Series B Convertible Preferred Stock Financing Round
Read more
  • First page «
  • Previous page ‹
  • Page 1
  • Page 2
  • Current page 3
Displaying 21 - 26 of 26


Email Alerts


FAQ


Contact IR


RSS Feeds
Contact us
info@ventyxbio.com
  • Privacy Policy
  • Terms Of Use
© 2023 Ventyx Biosciences, Inc. All rights reserved.
linkedin
Ventyx Biosciences, Inc.